Patient Blood Management In CARdiac sUrgical patientS: the ICARUS Study
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 479
- 试验地点
- 1
- 主要终点
- Percentage of patients receiving RBC transfusion within post-operative day 7
研究概览
简要总结
Nowadays up to 40% of patients undergoing cardiac surgery receives at least 1 unit of red blood cell transfusion during surgery or during the first week after surgery. Moreover up to 40% of these patients shows an absolute or relative iron deficiency, with or without anaemia.
The objective of this study is to assess whether to implement an adequate correction of iron according to current "patients blood management" recommendations might reduce RBC transfusion requirements in patients undergoing heart surgery.
Data obtained in patients included in the study will be compared to those of a case-control population selected from patients consecutively treated at the same department in the previous 2 years.
详细描述
Anemia is defined by the World Health Organization (WHO) as a value of hemoglobin (Hb) < 130 g/L in men and < 120 g/L in women. Anemia in surgical patients is a common and serious problem, in fact up to 40% of patients presenting for major surgery are anemic. Patients with pre-operative anemia have significantly higher rates of morbidity and mortality and are likely to receive red blood cell (RBC) transfusions. In turn, RBC are independently associated with worse outcome. Preoperative anemia mainly results from inadequate erythropoiesis owing to iron deficiency. Iron deficiency anemia (IDA) has a complex origin, including either absolute or functional iron deficiency (or iron sequestration). In absolute iron deficiency, iron stores are severely decreased, resulting in anaemia (IDA). Conversely, functional iron deficiency refers to insufficient iron mobilization despite normal or elevated iron stores (iron deficient erythropoiesis, IDE).The most rapid and simple method to correct anaemia is RBC transfusion. More than 30% of cardiac patients receives blood products in the peri-operative phase. However, blood transfusion itself is not without risk: in the setting of cardiac patients, even a single unit of blood transfused is reported to be associated to increased morbidity and mortality. Specifically, blood transfusions in cardiac surgery are associated with infections, ischemic postoperative morbidity, hospital stay, increased early and late mortality, and greater hospital costs. Preoperative correction of iron deficiency, with or without anaemia, is an integral part of the concept of the Patient Blood Management (PBM). Iron supplementation would increase the availability of iron stores and would trigger the process of erythropoiesis; the consequent relative lack of vitamin B12 and folic acid makes fundamental to restore also these 2 vitamins.
The objective of this study is to assess whether to implement an adequate correction of IDA and IDE according to current PBM recommendations might reduce RBC transfusion requirements in patients undergoing heart surgery. Data obtained in patients included in the study will be compared to those of a case-control population selected from patients consecutively treated at the same department in the previous 2 years.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •all adult patients candidate to planned heart surgery
排除标准
- •Pregnancy
- •Know allergy to iron, or B vitamin, or folic acid
- •Hyperferritinemia (ferritin blood value > 300 ng/ml).
- •patient's refusal
研究组 & 干预措施
cases
patients who fulfill the inclusion criteria
干预措施: Ferric carboxymaltose (Drug)
cases
patients who fulfill the inclusion criteria
干预措施: B vitamin (Drug)
cases
patients who fulfill the inclusion criteria
干预措施: Folic acid (Drug)
结局指标
主要结局
Percentage of patients receiving RBC transfusion within post-operative day 7
时间窗: within post operative day 7
Percentage of patients receiving RBC transfusion within post-operative day 7
次要结局
- length of stay in ICU(through study completion, an average of 1 year)
- number of allogeneic blood products administered(within the first 7 days post operative)
- acute kidney injury(within the first 7 days post operative)
- serious adverse events(within the first 12 hours after administration)
- mortality(within the first 7 days after surgery)
- Hb values at last postoperative control within 7 days from surgery(within post operative day 7)
- duration of mechanical ventilation(within the first 7 days post operative)
- infections requiring antibiotic treatment(within the first 7 days post operative)
- cost for the IDA/IDE treatment and blood product costs(within the first 7 days after surgery)
- major adverse cardiac and cerebrovascular events(within the first 7 days after surgery)
研究者
CORSI FILIPPO
Principal Investigator
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
